<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01188707</url>
  </required_header>
  <id_info>
    <org_study_id>LU0928</org_study_id>
    <nct_id>NCT01188707</nct_id>
  </id_info>
  <brief_title>A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer</brief_title>
  <official_title>A Clinical Phase I / II Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Copenhagen University Hospital at Herlev</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Onxeo</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Belinostat-Erlotinib trial is designed as an open, non randomized phase I / II trial to&#xD;
      assess the efficacy and safety of Belinostat in combination with Erlotinib in patients with&#xD;
      non-small cell lung cancer who are eligible for treatment with erlotinib.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Belinostat, developed by CuraGen, belongs to a new class of hydroxymat-type histone&#xD;
      deacetylase (HDAC) inhibitors. HDAC inhibitors, including Belinostat, has shown marked in&#xD;
      vitro and in vivo activity against a number of solid tumors and hematological cancers.&#xD;
      Belinostat has proven to be effective as a single agent or in combination with other&#xD;
      anticancer agents such as doxorubcin, paclitaxel, carboplatin, fluorouracil, bortezumib, and&#xD;
      there has been observed synergy between Belinostat or other HDAC inhibitors and EGFR&#xD;
      inhibitors gefinitinib and erlonitib.&#xD;
&#xD;
      Furthermore, the antineoplastic activity of Belinostat seen in preclinical experiments have&#xD;
      resulted in only moderate toxicity.&#xD;
&#xD;
      In the two Phase I trials of Belinostat for solid tumors and hematological malignancies&#xD;
      Belinostat have been well tolerated at doses up to 2000 mg daily in more than 100 patients.&#xD;
&#xD;
      Fatigue, nausea and vomiting has been the main side effects and with none or very mild&#xD;
      hematologic toxicity. Approximately 25% of patients in the study of solid tumors achieved&#xD;
      stable disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Dose over MTD reached&#xD;
  </why_stopped>
  <start_date type="Actual">October 1, 2010</start_date>
  <completion_date type="Actual">June 30, 2011</completion_date>
  <primary_completion_date type="Actual">June 30, 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>1 year</time_frame>
    <description>The primary purpose of the phase I part of the trial is to establish the tolerance dose (maximum tolerated dose (MTD) and dose limiting toxicity (DLT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>1 year</time_frame>
    <description>The phase II part of the study is to assess the efficacy of Belinostat and Erlotinib in combination assessed by disease control rate, defined as non - progression at 3 months / Stable disease or better) using RECIST response criteria version 1.1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Belinostat, Erlotinib, NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belinostat and Erlotinib</intervention_name>
    <description>The design of the first phase is a 3 +3 phase I trial. The Belinostat dose will start at 500 mg and will be increased with 250 mg until a maximum dose of 1500 mg, administered daily in 2/3 weeks. Each patient will at the same time receive 150 mg of Erlotinib daily continously.&#xD;
When the patient is enrolled at one dose level, there will be no further dose escalation for that individual patient.&#xD;
3 patients will be treated at each dose level.</description>
    <arm_group_label>Belinostat, Erlotinib, NSCLC</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed consent of an approved informed consent form&#xD;
&#xD;
          2. A. For the dose escalation phase: Patients with histological or cytological confirmed&#xD;
             non-small cell lung cancer who are rated suitable for treatment with Erlotinib B. For&#xD;
             MTD expansion phase: Patients diagnosed with non- small cell lung cancer rated&#xD;
             suitable for treatment with Erlotinib and with measurable disease according to RECIST&#xD;
             version 1.1&#xD;
&#xD;
          3. Performance status (ECOG) ≤ 2&#xD;
&#xD;
          4. Life expectancy at least 3 months&#xD;
&#xD;
          5. Age ≥ 18 years&#xD;
&#xD;
          6. Acceptable liver, kidney and bone marrow function, defined as:&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  ASAT, ALAT and alkaline phosphatase ≤ 3 x ULN (if liver metastases is ≤ 5 x ULN&#xD;
                  allowed)&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  WBC&gt; 2.5 x 109 / l, neutrophils&gt; 1.0 x 109 / l, platelets&gt; 100 x 109 / l&#xD;
&#xD;
               -  Hemoglobin&gt; 9.0 g / dl or&gt; 5.6 mmol / l&#xD;
&#xD;
          7. Acceptable coagulation: PT and APTT within ≤ 1.5 x ULN or in the therapeutic range if&#xD;
             given anticoagulant&#xD;
&#xD;
          8. A negative pregnancy test for women of childbearing age. In fertile men and women the&#xD;
             use of effective contraception methods are required during the trial&#xD;
&#xD;
          9. Serum potassium within normal range&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Treatment with experimental drugs within the last 4 weeks&#xD;
&#xD;
          2. Former anti-cancer therapy within the last 3 weeks before the start of experimental&#xD;
             treatment, including chemotherapy, radiotherapy, endocrine therapy or immunotherapy&#xD;
&#xD;
          3. Simultaneous presence of active infection or other concomitant present medical&#xD;
             condition likely to affect the experimental procedures, including significant&#xD;
             cardiovascular disease (New York Heart Association Class III or IV heart disease,&#xD;
             myocardial infarction within the past 6 months, unstable angina, congestive heart&#xD;
             failure requiring treatment, unstable arrhythmia or the need for antiarrhythmic drugs&#xD;
             or signs of ischemia on ECG, marked baseline prolongation of QT / QTc interval, for&#xD;
             example repeated demonstration of a QTc interval&gt; 500 msec; long QT syndrome; required&#xD;
             the use of concurrent medication on dosage belinostat days, which may cause torsades&#xD;
             de pointes (see Appendix 1).&#xD;
&#xD;
          4. Altered mental status that prevents understanding of the informed consent process and&#xD;
             / or execution of the necessary experiments&#xD;
&#xD;
          5. Secondary malignancy present (previous malignancy accepted if cured by treatment for &gt;&#xD;
             3 years ago)&#xD;
&#xD;
          6. Intestinal obstruction or threatening bowel obstruction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon L Andersen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Oncology Copenhagen University Hospital Herlev</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept of Oncology Copenhagen University Hospital Herlev</name>
      <address>
        <city>Copenhagen</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 24, 2010</study_first_submitted>
  <study_first_submitted_qc>August 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2010</study_first_posted>
  <last_update_submitted>October 16, 2020</last_update_submitted>
  <last_update_submitted_qc>October 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Anders Mellemgaard</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Non small cell lung cancer</keyword>
  <keyword>Belinostat</keyword>
  <keyword>Erlotinib</keyword>
  <keyword>HDAC inhibitor</keyword>
  <keyword>Phase I/II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Belinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

